Last reviewed · How we verify

Cefepime Injection

Murdoch Childrens Research Institute · FDA-approved active Small molecule

Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections including pneumonia, febrile neutropenia, urinary tract infections, and intra-abdominal infections, Empiric therapy for hospitalized patients with suspected gram-negative or gram-positive bacterial infections.

At a glance

Generic nameCefepime Injection
SponsorMurdoch Childrens Research Institute
Drug classFourth-generation cephalosporin
TargetPenicillin-binding proteins (PBPs)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Cefepime works by disrupting the cross-linking of peptidoglycan in the bacterial cell wall, leading to cell wall instability and bacterial death. It has broad-spectrum activity against both gram-positive and gram-negative bacteria, including some Pseudomonas aeruginosa strains. As a fourth-generation cephalosporin, it has enhanced activity against gram-negative organisms compared to earlier generations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: